Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

<p>Supplementary Tables</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Koichi Tomoshige (15304682) (author)
Rannpháirtithe:	William D. Stuart (15304685) (author), Iris M. Fink-Baldauf (15304688) (author), Masaoki Ito (15304691) (author), Tomoshi Tsuchiya (15304694) (author), Takeshi Nagayasu (15304697) (author), Tomoki Yamatsuji (15304700) (author), Morihito Okada (15038418) (author), Takuya Fukazawa (15304703) (author), Minzhe Guo (15304706) (author), Yutaka Maeda (15304709) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Cancer Biology Molecular and Cellular Biology Gene Regulation Promoter/enhancer analysis Lung Cancer Oncogenes & Tumor Suppressors Kras
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
de réir: Nicholas T. Younger (14956251)
Foilsithe / Cruthaithe: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
de réir: Nicholas T. Younger (14956251)
Foilsithe / Cruthaithe: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
de réir: Nicholas T. Younger (14956251)
Foilsithe / Cruthaithe: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
de réir: Nicholas T. Younger (14956251)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 1 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
de réir: Dhruv Chachad (14954640)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 2 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
de réir: Dhruv Chachad (14954640)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 3 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
de réir: Dhruv Chachad (14954640)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 4 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
de réir: Dhruv Chachad (14954640)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 5 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
de réir: Dhruv Chachad (14954640)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
de réir: Man Xu (14963249)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
de réir: Man Xu (14963249)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
de réir: Man Xu (14963249)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
de réir: Man Xu (14963249)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
de réir: Man Xu (14963249)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
de réir: Man Xu (14963249)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
de réir: Man Xu (14963249)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
de réir: Man Xu (14963249)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
de réir: Caleb N. Seavey (15056489)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
de réir: Caleb N. Seavey (15056489)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_qq7ojak4c7iu4fpbp4pol9j0ep